SEC Comment Letter for 4D Molecular Therapeutics, (FDMT) — May 8, 2026
4D Molecular Therapeutics, Inc.
Date: May 8, 2026 · CIK: 0001650648 · Accession: 0000000000-26-004734
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295650
Letter
Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 Filed May 7, 2026 File No. 333-295650 Dear David Kirn: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions.
May 8, 2026
David Kirn Chief Executive Officer 4D Molecular Therapeutics, Inc. 5858 Horton Street #455 Emeryville, CA 94608
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: John Williams
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 8, 2026 David Kirn Chief Executive Officer 4D Molecular Therapeutics, Inc. 5858 Horton Street #455 Emeryville, CA 94608 Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 Filed May 7, 2026 File No. 333-295650 Dear David Kirn: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John Williams </TEXT> </DOCUMENT>